Citable filing context
INCY's research view summarizes recent SEC filing context, starting with earnings from Jul 28, 2026.
| Filed | Item | Context |
|---|---|---|
| Jul 28, 2026 | earnings | Incyte reported Q2 2026 total revenue of $1.67 billion and updated its full-year 2026 financial guidance. |
| Jul 6, 2026 | acquisition | Incyte completed its acquisition of Vega Therapeutics for $1.25 billion upfront and up to $750 million in milestones. |
| Jun 22, 2026 | legal_settlement | Incyte settled litigation with CMS over Opzelura, expecting a $246 million one-time non-cash benefit. |
| Jul 28, 2026 | Guidance: hematology_oncology_net_sales | 860.00 to 890.00 |
| Jul 28, 2026 | Guidance: jakafi_net_sales | 3220.00 to 3270.00 |
| Jul 28, 2026 | Guidance: opzelura_net_sales | 1050.00 to 1100.00 |
| Jul 28, 2026 | mda_quarterly | Incyte Corporation reported strong financial growth for the first half of 2026, with net income rising to $888.9 million compared to $563.2 million in the prior-year period. Total net sales reached $2.59 billion, driven by robust demand for its hematology and oncology portfolios. Lead product JAKAFI (ruxolitinib) remains a primary revenue driver, bolstered by the second-quarter 2026 launch of JAKAFI XR. OPZELURA (ruxolitinib) cream also saw significant growth in atopic dermatitis and vitiligo, further aided by a $246 million one-time non-cash benefit following a settlement with CMS regarding Medicaid rebate regulations. The company’s pipeline continues to advance, notably with the Phase 3 success of tafasitamab in first-line diffuse large B-cell lymphoma and the acquisition of Vega Therapeutics to secure the late-stage asset latarcibart for von Willebrand disease. Povorcitinib is also progressing toward potential 2027 U.S. approvals in hidradenitis suppurativa and vitiligo. Despite this momentum, Incyte faces ongoing risks, including heavy reliance on JAKAFI, potential generic competition, and the complexities of global regulatory and reimbursement environments. With $4.5 billion in cash and marketable securities as of June 30, 2026, the company maintains a solid liquidity position to support its ongoing R&D investments and strategic growth initiatives. |
| Apr 28, 2026 | mda_quarterly | Incyte reported Q1 2026 net income of $303.3 million and total revenues of $1.27 billion, driven by growth in JAKAFI ($757.8 million), OPZELURA ($143.0 million), and the commercial ramp of NIKTIMVO and ZYNYZ. JAKAFI remains the primary revenue driver, though the company is diversifying across its hematology, oncology, and inflammation franchises. Key near-term catalysts include the anticipated mid-2026 launch of JAKAFI XR and a supplemental BLA filing for tafasitamab in first-line DLBCL during H1 2026. Povorcitinib demonstrated positive Phase 3 results for vitiligo, and its NDA for hidradenitis suppurativa was accepted in Q1 2026. In oncology, the Phase 3 DAWN-303 trial for the KRAS G12D inhibitor INCB161734 in metastatic pancreatic cancer initiated in Q1 2026. A significant regulatory risk is the ongoing litigation against CMS regarding whether OPZELURA is a "line extension" of JAKAFI, for which the company has accrued $245.9 million in potential rebates. Incyte maintains a strong liquidity position with $4.0 billion in cash and marketable securities and generated $369.4 million in net cash from operating activities during the quarter. |
Source: SEC EDGAR filing text and events; period Jul 28, 2026; filed Jul 28, 2026.
INCY company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.